Tamibarotene in Higher-Risk Myelodysplastic Syndrome (MDS)

home / insights / tamibarotene-in-higher-risk-myelodysplastic-syndrome-mds-

Dr Gustavo Rivero discusses how and where tamibarotene might fit into the treatment landscape for patients with higher-risk myelodysplastic syndrome (MDS).

Overview of Myelodysplastic Syndrome and the Importance of Biomarker Testing

EP. 1: Overview of Myelodysplastic Syndrome and the Importance of Biomarker Testing

Gustavo Rivero, MD
June 17th 2022

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.

RARA Gene Expression in Higher-Risk MDS

EP. 2: RARA Gene Expression in Higher-Risk MDS

Gustavo Rivero, MD
June 17th 2022

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

A Potential Role for Tamibarotene in the Treatment of Higher-Risk MDS

EP. 3: A Potential Role for Tamibarotene in the Treatment of Higher-Risk MDS

Gustavo Rivero, MD
June 28th 2022

Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.

SELECT-MDS-1: Review of Study Design and Objectives

EP. 4: SELECT-MDS-1: Review of Study Design and Objectives

Gustavo Rivero, MD
June 28th 2022

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.

Future Perspectives in Higher-Risk MDS

EP. 5: Future Perspectives in Higher-Risk MDS

Gustavo Rivero, MD
July 6th 2022

Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.